Group 1 - The International Atomic Energy Agency (IAEA) conducted a five-day regional training program in Suzhou focused on quality assurance in radiation therapy, attended by 35 medical professionals from 14 countries in the ASEAN and Gulf Cooperation Council regions [1][3] - The training was co-hosted by the IAEA and China's National Atomic Energy Agency, with support from local institutions, aiming to enhance nuclear medical cooperation among member states [3] - The QUATRO comprehensive clinical audit method was emphasized during the training, which included theoretical lectures, case studies, and practical simulations to improve the safety and standardization of cancer treatment [3] Group 2 - The training coincided with the 27th World Cancer Day, featuring a regional public awareness event on cancer prevention and treatment, highlighting the hospital's patient-centered service philosophy [5] - Experts from the Nuclear Industry General Hospital presented on early detection, precise treatment strategies, and comprehensive management of common cancers, showcasing the application of the MDT model [5][7] - Participants visited key facilities, including the National Key Laboratory of Radiation Medicine and Radiation Protection and the East China Irradiation Company, gaining insights into China's advancements in radiation medicine and nuclear technology applications [9]

Core Viewpoint - The article reports the passing of Sun Yan, a prominent figure in oncology in China, who contributed significantly to the field and passed away on January 24, 2026, at the age of 96 [1]. Group 1: Personal Background - Sun Yan was born in February 1929 in Hebei Province and graduated from Peking Union Medical College in 1956 with a doctoral degree in medicine [3]. - He began his career at Peking Union Medical College Hospital and joined the Chinese Academy of Medical Sciences Cancer Hospital in 1959, where he held various leadership positions [3]. Group 2: Contributions to Oncology - Sun Yan was a pioneer in the development of oncology in China, advocating for comprehensive treatment approaches and leading the establishment of the discipline from the ground up [3]. - He was instrumental in the development of new drug research and clinical translation, as well as exploring integrated Chinese and Western medicine for cancer prevention and treatment [3]. - His work on the Zhenqi Fuzheng series of products significantly contributed to local pharmaceutical development and poverty alleviation efforts [3]. Group 3: Recognition and Awards - Sun Yan received numerous accolades, including the National Science and Technology Progress Award (First Class), recognition as an advanced worker in the national health system, and the Chinese Physician Award [3]. - He was elected as an academician of the Chinese Academy of Engineering in 1999 and enjoyed special government allowances from the State Council [3].

Core Viewpoint - Hainan Province Cancer Hospital leverages the benefits of the Free Trade Port policy to introduce new technologies and improve patient care, aiming to provide comprehensive cancer treatment services within the island [2][4][9] Group 1: Hospital Achievements - The hospital has served a total of 2.546 million patients and conducted over 700 health education and free clinic events since its establishment ten years ago [2] - It has successfully implemented more than 60 new techniques that fill gaps in local healthcare services, promoting the goal of "no major illness leaving the island" [2] Group 2: Policy Utilization - The hospital utilizes the Free Trade Port policy to introduce innovative drugs and medical devices, significantly reducing patient wait times for treatments [4] - For instance, a patient from Chongqing received a new cancer treatment that was not yet approved for use in mainland China, highlighting the hospital's ability to provide timely and advanced care [4] Group 3: Talent Development - The hospital emphasizes the importance of talent cultivation alongside technological advancements, establishing a comprehensive system for attracting, training, and utilizing medical professionals [5][7] - A partnership with Hainan Medical University aims to enhance local medical talent through specialized training and collaborative research in oncology [7] Group 4: Preventive Care Initiatives - The hospital has conducted extensive community outreach programs, including free early cancer screening events, benefiting over 550,000 residents and identifying high-risk individuals for early intervention [8] - The hospital has completed over 65,000 risk assessments and 40,000 free clinical screenings as part of the national early cancer diagnosis and treatment initiative [8] Group 5: Future Outlook - With the official launch of the Hainan Free Trade Port, the hospital views this as both a challenge and an opportunity to enhance its services and contribute to the health of the community [9]

Core Viewpoint - Suzhou has launched a pioneering integrated cancer prevention and treatment system, focusing on 13 common types of cancer, aiming to enhance the quality of medical resources available to patients locally through a collaborative approach involving multiple hospitals and disciplines [1][2]. Group 1: Integrated Cancer Prevention and Treatment System - The integrated system allows for remote consultations where doctors move to the patient rather than the other way around, ensuring patients can access high-quality medical resources close to home [1]. - The system includes a collaboration among various hospitals, such as Suzhou University Affiliated Second Hospital and Suzhou Municipal Hospital, to provide multidisciplinary consultations for patients [1]. - The initiative is part of a broader effort by the Suzhou government to address the rising number of cancer patients, which has reached approximately 50,000 new cases annually, with a trend towards younger patients [2]. Group 2: Implementation and Expansion - The first pilot areas for this system include Zhangjiagang, Taicang, Wuzhong District, Xiangcheng District, and Suzhou Industrial Park, with plans to expand the implementation after establishing standardized practices [3]. - The system aims to leverage the influence of leading hospitals to create a comprehensive cancer prevention network, promoting standardized diagnosis and treatment across the region [2][3]. - The initiative is supported by the establishment of the Suzhou Cancer Prevention Academic Committee, which includes top experts to enhance the collaborative framework [2].

Core Viewpoint - The recent election results for the Chinese Academy of Sciences and the Chinese Academy of Engineering highlight a significant focus on cancer research, particularly in liver and gastrointestinal cancers, with notable advancements in prevention and early diagnosis [3][4]. Group 1: New Academicians - A total of 73 new academicians were elected to the Chinese Academy of Sciences, and 71 to the Chinese Academy of Engineering [3]. - Among the newly elected academicians, significant contributions come from experts in clinical medicine, particularly in cancer research [3]. Group 2: Focus on Liver Cancer - The field of liver cancer remains a critical area of research, with approximately 900,000 new cases globally each year, and China accounting for nearly half of these cases [3]. - A major report published in The Lancet by academicians Zhou Jian and Fan Jia indicates that at least 60% of liver cancer cases are preventable through risk factor reduction [4]. Group 3: Innovations in Diagnosis and Treatment - Zhou Jian and Fan Jia have developed a miRNA-based early diagnosis model for liver cancer, which has been successfully transformed into a clinical application, significantly improving early detection rates compared to traditional markers [5]. - The overall survival rate for treated patients has reached an international leading level due to innovative personalized treatment strategies [5]. Group 4: Gastrointestinal Cancer Research - Gastrointestinal cancer also has a high incidence rate in China, with significant contributions from academician Fang Jingyuan in early diagnosis, prevention, and comprehensive treatment strategies [5].

Core Insights - The newly elected academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering highlight a concentration in the field of oncology and major diseases, with a total of 73 and 71 academicians elected respectively [1][3]. Group 1: Elected Academicians - Among the newly elected academicians, notable experts in clinical medicine include Zhou Jian from Zhongshan Hospital affiliated with Fudan University and Fang Jingyuan from Renji Hospital affiliated with Shanghai Jiao Tong University [1]. - Other elected academicians in clinical medicine include Cai Xiujun from Shao Yifu Hospital affiliated with Zhejiang University and Wang Yongjun from Beijing Tiantan Hospital affiliated with Capital Medical University [1]. Group 2: Focus on Liver Cancer - Zhou Jian specializes in clinical and basic research on liver cancer and has received the National Science and Technology Progress Award five times; he emphasizes that liver cancer can be managed as a chronic disease [3]. - Zhou Jian and Fang Jingyuan published a significant report in The Lancet, indicating that at least 60% of liver cancer cases are preventable by reducing risk factors such as viral hepatitis and alcohol consumption [3]. - A miRNA early diagnosis model for liver cancer developed by Zhou Jian and Fang Jingyuan has been successfully transformed into a clinical application, with over 5 million tests conducted, significantly improving early detection rates compared to traditional markers [3]. Group 3: Focus on Gastrointestinal Cancer - Fang Jingyuan has made significant contributions in the field of gastrointestinal cancer, particularly in early warning, diagnosis, prevention, and comprehensive treatment [4]. - Fang Jingyuan has innovatively analyzed gut microbiota to assess the effectiveness of postoperative chemotherapy and immunotherapy for colorectal cancer [4].

Core Viewpoint - The 2025 CACA Northeast Integrated Oncology Conference was held in Shenyang, focusing on the theme of "Cancer Prevention and Treatment, Winning through Integration" [1] Group 1: Conference Overview - The conference was organized by the China Anti-Cancer Association (CACA) and co-hosted by various institutions, including the World Association of Integrated Oncology (WAIO) [1] - The event aimed to promote the "Chinese solution" for cancer prevention and treatment globally, with over 400 collaborative units established across the country [1] Group 2: Key Messages from Leaders - Fan Daiming, the chairman of the conference and CACA president, emphasized the importance of the CACA guidelines, which are disseminated in 16 languages [1] - Chen Yanlan, from the Liaoning Provincial Health Commission, highlighted the integration of cancer prevention into the overall health strategy of Liaoning Province [1] Group 3: Hospital's Role in Cancer Treatment - Liu Hongxu, the secretary of the Liaoning Provincial Tumor Hospital, stated that traditional treatment models are inadequate for the complexities of cancer, advocating for integrated medical approaches [2] - The hospital aims to enhance early diagnosis, standardized treatment, and comprehensive management of cancer patients [2]

Core Insights - The 28th CSCO Annual Meeting was held in Jinan, Shandong, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hysco Clinical Oncology Research Foundation, featuring 75 academic sessions and around 1,500 expert speakers, including over 30 international experts from 15 countries [1][2] Group 1: Academic Collaboration - CSCO aims to deepen international cooperation in cancer prevention and treatment, with dialogues planned with high-level representatives from ESMO and other organizations to explore new opportunities [2] - ASCO expressed its commitment to maintaining a strong collaborative relationship with CSCO, emphasizing joint scientific meetings and various initiatives to enhance global oncology development [3] Group 2: Recognition and Awards - CSCO awarded the Annual Achievement Award to three scholars for their significant contributions to clinical oncology, highlighting the importance of innovation and impact in the field [4] - Ten outstanding research papers were recognized, focusing on treatment strategies, new drug development, biomarker exploration, and real-world data analysis, showcasing the depth and innovation of Chinese oncology research [4] Group 3: Academic Content and Innovation - The conference featured 75 academic sessions, emphasizing original research and evidence-based medicine, with a focus on new therapies like ADC and CAR-T/CAR-NK, and addressing major cancer types through AI-focused sessions [6] - The meeting also highlighted the management of cancer as a chronic disease, with a focus on patient quality of life and long-term survival, alongside the release of new clinical guidelines [6] Group 4: Future Directions - The theme of the conference, "Standardized Diagnosis and Treatment, Innovative Leadership," included 530 academic reports and 196 oral presentations, aiming to translate research achievements into clinical practice [7] - The event serves as a key platform for the Chinese oncology community to showcase achievements and foster collaboration, ultimately enhancing cancer prevention and treatment standards in China [7]

Core Viewpoint - The establishment of the Inner Mongolia Tumor Specialty Alliance marks a new development phase in cancer prevention and treatment in Inner Mongolia, aiming to optimize medical resource allocation and enhance grassroots diagnostic capabilities [1][2] Group 1: Alliance Formation and Objectives - The alliance is led by the Inner Mongolia Hospital of Peking University Cancer Hospital, leveraging its resources to improve diagnostic levels through expert dispatch, remote consultations, and standardized training [1] - The initiative aims to provide high-quality cancer treatment services locally, reducing the burden of seeking medical care and enhancing health accessibility for residents [1] Group 2: Mechanisms and Practices - The alliance will establish a long-term mechanism for standardized cancer diagnosis and treatment, early screening, talent cultivation, and research collaboration [1] - A two-way referral system and a tumor disease referral guide will be implemented to facilitate patient transfers between different levels of medical institutions [1] Group 3: Training and Education - The alliance will create a training system for tumor specialists and conduct relevant training programs [2] - Remote medical platforms will be utilized for lectures, case discussions, and academic exchanges to enhance the service capabilities of grassroots medical institutions [2] - Future initiatives include continuing medical education projects, academic seminars, and clinical research on new interventional techniques in oncology [2]

Core Insights - The event marked the recognition of China Resources Pharmaceutical Group as a member of the China Anti-Cancer Association, highlighting the collaboration between the two entities in cancer prevention and treatment [2][4][6] Group 1: Event Overview - The event was themed "Empowerment through Integration" and included a visit to the innovation center of China Resources Pharmaceutical Group, showcasing its patient-centered innovations over 75 years [4][5] - Key figures from the China Anti-Cancer Association, including its president and vice presidents, attended the event, emphasizing the importance of collaboration in cancer treatment [2][6] Group 2: Strategic Initiatives - The China Anti-Cancer Association introduced 17 strategic measures under the guidance of integrated medicine, aiming to enhance cancer prevention and treatment in China [5][6] - The association's "China Cancer Integrated Diagnosis and Treatment Guidelines" established a comprehensive system for cancer care, including over 70 technical guidelines and 60 cancer type guidelines [5][6] Group 3: Industry Collaboration - China Resources Pharmaceutical Group aims to integrate resources across research, education, and application to improve patient access to innovative drugs, positioning itself as a leader in the pharmaceutical distribution sector [6][9] - The company plans to enhance collaboration with the China Anti-Cancer Association to build a new ecosystem for cancer prevention and treatment, supporting the Healthy China strategy [6][9] Group 4: Challenges and Opportunities - The Chinese pharmaceutical industry is entering a new phase driven by product innovation, but faces challenges such as shortened product life cycles and commercialization difficulties [6][9] - The company is leveraging its extensive distribution network and experience to improve patient accessibility and address the challenges in drug availability and payment [6][9]